- Trial phase
- Phase 3
- Time to market
- At least 3-4 years away, if ever. PROVE-FA has a 24-month primary endpoint and began enrolling in Q3 2026, so topline data would not be available before late 2028, followed by NDA resubmission and FDA review.
- Why 3/10
- No hard dated binary catalyst exists in the next ~12 months: the PDUFA decision (August 2025) resulted in a CRL, and the next study (PROVE-FA) is a 24-month open-label trial that began enrolling in Q3 2026 with no announced readout date. Vatiquinone is also not the primary value driver for PTC, which has multiple approved products.
The next catalyst is the PROVE-FA open-label Phase 3 study (initiated Q3 2026), which will enroll ~120 FA patients aged 7-21 and compare against matched natural history controls over 24 months. A positive readout could support NDA resubmission, but the open-label design may not satisfy the FDA's request for an "adequate and well-controlled study." No topline data is expected before late 2028 at the earliest, so vatiquinone is unlikely to be a near-term stock driver for PTCT.
Price Chart
Executive Summary
Vatiquinone (EPI-743/PTC-743) is an oral 15-lipoxygenase inhibitor being developed by PTC Therapeutics for Friedreich's ataxia (FA), a rare neurodegenerative disease. The FDA issued a Complete Response Letter in August 2025 declining approval after the pivotal MOVE-FA Phase 2/3 trial missed its primary endpoint (mFARS at 72 weeks). In response, PTC initiated PROVE-FA, a new open-label Phase 3 study in Q3 2026 using matched natural history controls, targeting ~120 patients aged 7-21. With no near-term binary catalyst and the drug already rejected by the FDA, vatiquinone is a minor pipeline component for PTC, which has multiple approved products generating revenue.
How It Works
Vatiquinone is an oral drug that blocks an enzyme called 15-lipoxygenase, which is a key regulator of ferroptosis, a type of inflammatory cell death. By inhibiting this enzyme, vatiquinone aims to reduce brain inflammation and oxidative stress, potentially slowing the progression of Friedreich's ataxia, a rare genetic neurodegenerative disease that causes progressive loss of coordination and muscle function.
Trial Status
The MOVE-FA Phase 2/3 trial (NCT04577352) completed but failed its primary endpoint. A new Phase 3 open-label study called PROVE-FA (NCT07681713) began enrolling in Q3 2026, targeting ~120 FA patients aged 7-21 with a 24-month primary endpoint comparing against matched natural history controls.
The Two-Sided Case
Upcoming Catalysts
- PROVE-FA enrollment updates (ongoing, Q3 2026 initiation confirmed)
- Interim data from PROVE-FA (no date announced)
- Potential NDA resubmission (contingent on positive PROVE-FA results, likely 2028+ if at all)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report